Condition: Hypothyroidism · Thyroid Cancer · Thyroid · Sponsor: University Hospital of North Norway
Levothyroxine is the most used thyroid hormone replacement when the thyroid gland is failing. Because dosage adjustment normally takes several months, the investigators have developed a decision support tool (DST) that predicts optimal dosage based on repeated blood samples the first 2 weeks after initiation of therapy. In this randomized study the investigators will include patients that start levothyroxine therapy after total thyroidectomy. The use of DST to advice the physician about an early dosage adjustment will be compared with common clinical practice, that is dosage adjustment every 2 months. The effect of DST use will be assessed by studying the possible relationship between fast optimal dose adjustment, patient reported outcome measures, and ability to work.
This description comes directly from the study's public registry record.
Vegard Brun, PhD · 0047 77669260 · vegard.heimly.brun@unn.no
Solveig Brun, cand.med · 004745253006 · solveig.konst@unn.no
Always discuss trial participation with your own doctor first.
| Haukeland University Hospital | Bergen, Norway | Recruiting |
| Oslo University Hospital | Oslo, Norway | Recruiting |
| University Hospital of North Norway | Tromsø, Norway | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06455371